Saturday 17 October 2026
Export FLGT’s income statement to Excel — free account
Fulgent Genetics, Inc.
FLGT Healthcare Diagnostics & Research
Fulgent Genetics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $322.7 million, up 13.8% from fiscal 2024. In the quarter to June 2026, revenue grew 4.38%, EPS fell 69.4% and free cash flow grew 25.4%, each against the same quarter a year earlier.
19.81
1.53
−7.17%
Follow FLGT
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
7 | 4 | 2 | 5 |
| (3.81%) | (5.41%) | (6.81%) | (8.01%) | ||
| (3.51%) | (4.97%) | (6.25%) | (7.37%) | ||
ROIC |
(5.96%) | (7.39%) | (8.62%) | (10.34%) | |
Return on Tangible Assets |
(7.86%) | (10.47%) | (14.61%) | (17.01%) | |
Average Days of Receivables |
82.34 | 95.88 | 78.93 | 73.17 | |
Free Cash Flow per Share |
(0.65) | (4.04) | (3.66) | (3.71) | |
Free Cash Flow |
(19.84) | (124.21) | (113.16) | (103.78) | |
Capital Expenditures |
(21.37) | (22.57) | (23.05) | (20.08) | |
| Other line items | |||||
Cash ROIC |
(1.33%) | (8.61%) | (8.57%) | (8.28%) | |
Accounts Receivable Turnover |
4.91 | 4.20 | 4.55 | 4.56 | |
Accounts Payable Turnover |
9.79 | 10.36 | 9.98 | 12.12 | |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
35.61 | 35.50 | 39.27 | 27.21 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
(0.09) | (0.12) | (0.11) | (0.08) | |
Research and Development Expense of Revenue |
16.43% | 16.71% | 17.38% | 17.52% | |
Selling, General and Administrative Expense of Revenue |
44.78% | 49.60% | 51.88% | 52.46% | |
Share Based Compensation of Revenue |
12.90% | 12.27% | 12.15% | 11.58% | |
Interest Coverage |
(717.10) | (1,214.61) | (1,357.99) | (1,019.02) | |
Operating CF/Net income |
(0.04) | 1.68 | 1.22 | 0.99 | |
Depreciation/Fixed assets |
0.16 | 0.17 | 0.17 | 0.20 | |
Capex/Depreciation |
(1.16) | (1.19) | (1.16) | (0.91) | |
Revenue per Share |
10.26 | 10.48 | 10.37 | 11.57 | |
Operating CF per Share |
0.05 | (3.30) | (2.92) | (2.99) | |
Capex per Share |
(0.69) | (0.73) | (0.75) | (0.72) | |
Capex to Sales |
0.07 | 0.07 | 0.07 | 0.06 |
Columns are period end dates